Interferon Beta Initiated Development of Immunogenic T1 B cells in Lupus
干扰素 Beta 启动狼疮中免疫原性 T1 B 细胞的发育
基本信息
- 批准号:10477180
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-10-01 至 2022-09-30
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntigensApoptoticAutoantibodiesAutoantigensAutoimmune DiseasesAutoimmunityAutomobile DrivingB-Cell Antigen ReceptorB-Lymphocyte SubsetsB-LymphocytesBiological Response Modifier TherapyBone MarrowCaringCell CompartmentationCell MaturationCell SeparationCell SurvivalCellsChimera organismChronicClinicalCluster AnalysisDataDefectDevelopmentDiseaseElementsEnvironmental Risk FactorEventExhibitsFOXP3 geneFlow CytometryFundingGene ExpressionGene Expression ProfileGene Expression ProfilingGenerationsGenetic Predisposition to DiseaseGenetic TranscriptionGoalsGrantIFNAR1 geneIRF3 geneImmunocompetentImmunoglobulin IdiotypesIn VitroInterferon ReceptorInterferon Type IInterferon-alphaInterferon-betaInterferonsInterleukin-10LupusMaintenanceMature B-LymphocyteMediatingModelingMolecularMouse StrainsMusNuclearNucleic AcidsPathogenesisPathogenicityPathway interactionsPatientsPhenotypePlayPopulationProcessProductionReporterResolutionRoleSignal TransductionSpecificitySystemic Lupus ErythematosusT-LymphocyteTLR7 geneTechniquesTestingTherapeuticTransitional CellUp-RegulationWorkautocrineautoreactive B cellautoreactivitybasecytokinedesignexperimental studyimmunogenicimprintimprovedin vivoinsightinter-individual variationmigrationmouse modelnovelprecision medicinereceptor-mediated signalingresponsesingle cell analysistherapeutic targettooltranscription factor
项目摘要
Systemic lupus erythematosus (SLE) is a chronic debilitating disease that is characterized by high titers of
autoantibodies with specificity for nuclear autoantigens. It is considered to arise from interactions between
underlying genetic susceptibility and environmental factors, with different combinations resulting in inter-
individual variations in disease manifestations and therapeutic responsiveness. Directed therapeutic targeting
of specific pathways has not proven effective, which suggests that the current understanding of pathogenesis
is incomplete. The goal of the proposed project is to test the hypothesis that the survival of immature
autoreactive B cells, the preferential development of antinuclear autoreactive B cells and the status of mature
autoreactive B cells (immunocompetent vs. anergic/tolerogenic) is decided during the transitional stage 1 (T1)
of development and requires constitutive T1 B cell expression of interferon β (IFNβ).
This paradigm shifting hypothesis is based on data generated using a combination of mixed-bone marrow
chimeras, flow cytometry with tetramer or idiotype antibody selection, and high-throughput single-cell analysis
to interrogate type I interferon (IFN) networks in B cell from patients with SLE and lupus-prone BXD2 mice. The
data suggest that the currently known molecular and cellular aberrations are preceded by a single primary
pathogenic event, i.e., production of IFNβ by T1 B cells. The data suggest that the survival of the very early T1
cells is dependent on endogenous expression of IFNβ. This subset of T1 B cells express endogenous IFNβ,
which leads to their development into T1 B cells that produce IFNα. The ability of T1 B cells to escape negative
B-cell receptor (BCR)-mediated selection is dictated by the type I IFN-determined responsiveness of this T1
subset to BCR-mediated signaling in combination with stimulation of TLR signaling (TLR7 or TLR9) by
apoptotic debris. This preferentially permits escape of nucleic antigen-autoreactive B cells. We have further
identified that the T1 B cell compartment contains distinct subsets of cells. As these included subsets with
transcriptional profiles that parallel the phenotypes of mature and anergic suppressive regulatory (Breg) cells
and their immunogenic counterparts that predominate in SLE, our new data suggest that this phenotypic switch
in the mature B cells is imprinted during the T1 stage. These data also suggest that development of type I IFN
network associated T1 B cells in BXD2 mice is associated with type I IFN-inducing transcription factors (IRF3
and IRF7) whereas induction of the Foxp3+ regulatory T1 B cells is associated with transcription factor, ID3.
Notably, these data not only suggest suppression of precursors of T1-Breg is a novel pathogenic
framework in SLE but also provide the tool, i.e., the gene expression signatures in sorted transitional B cells,
that enable its analysis. We will test the critical elements of our overall hypothesis through three Specific Aims
that will: (1) Distinguish the roles of the constitutive IFNβ signaling and the microenvironmental signals in
driving the development of T1 B cells; (2) Identify if the initial T1 B cell transcriptional imprinting is maintained
at the T2/MZP-MZ-FO stage of development; and (3) Determine if T1 B-cell endogenous IFNβ promotes a type
I IFN network that suppresses the precursors of regulatory B cells at the T1 stage in SLE patients. The
scientific premises of the proposed work include the parallels between transcriptional profiles in the T1 B cells
and mature B cells and the segregation of type I IFN associated vs Breg associated transcriptional profiles in
the T1 B cells. We have acquired reporter mouse strains for IFNβ, IL-10, Foxp3 and Id3 to interrogate discreet
developmental stages within and derived from transitional T1 B subsets.
The information gained will have a broad-based impact on the field and improve the care of VA patients
with SLE by identifying strategies to improve the efficacy of targeted biologic therapies together with non-
invasive precision medicine guided-approaches.
系统性红斑狼疮 (SLE) 是一种慢性衰弱性疾病,其特征是高滴度的
对核自身抗原具有特异性的自身抗体被认为是由之间的相互作用产生的。
潜在的遗传易感性和环境因素,不同的组合会导致相互影响
疾病表现和治疗反应的个体差异。
特定途径的研究尚未被证明有效,这表明目前对发病机制的理解
所提出的项目的目标是检验不成熟的生存的假设。
自身反应性 B 细胞、抗核自身反应性 B 细胞的优先发育和成熟状态
自身反应性 B 细胞(免疫活性与无能/耐受性)在过渡阶段 1 (T1) 期间决定
发育过程中需要 T1 B 细胞组成型表达干扰素 β (IFNβ)。
这种范式转变假设基于使用混合骨髓组合生成的数据
嵌合体、四聚体或独特型抗体选择的流式细胞术以及高通量单细胞分析
研究 SLE 患者和易患狼疮的 BXD2 小鼠 B 细胞中的 I 型干扰素 (IFN) 网络。
数据表明,目前已知的分子和细胞畸变之前有一个单一的主要畸变
致病事件,即 T1 B 细胞产生 IFNβ。数据表明,非常早期的 T1 细胞能够存活。
T1 B 细胞依赖于内源性 IFNβ 的表达。
这导致它们发育成产生 IFNα 的 T1 B 细胞 T1 B 细胞逃避阴性的能力。
B 细胞受体 (BCR) 介导的选择由该 T1 的 I 型 IFN 决定的反应性决定
BCR 介导的信号传导的子集与 TLR 信号传导(TLR7 或 TLR9)的刺激相结合
凋亡碎片优先允许核酸抗原自身反应性 B 细胞逃逸。
确定 T1 B 细胞区室包含不同的细胞子集,因为这些细胞子集包含
与成熟和无能抑制调节 (Breg) 细胞表型相似的转录谱
及其在 SLE 中占主导地位的免疫原性供体,我们的新数据表明这种表型转变
这些数据还表明,I 型干扰素的发育在成熟 B 细胞中被印记。
BXD2 小鼠中网络相关的 T1 B 细胞与 I 型 IFN 诱导转录因子 (IRF3
和 IRF7),而 Foxp3+ 调节性 T1 B 细胞的诱导与转录因子 ID3 相关。
值得注意的是,这些数据不仅表明抑制 T1-Breg 前体是一种新的致病性
SLE 中的框架,还提供了工具,即分选的移行 B 细胞中的基因表达特征,
我们将通过三个具体目标来测试我们总体假设的关键要素。
这将:(1)区分组成型 IFNβ 信号和微环境信号在
驱动T1 B细胞的发育;(2)确定初始T1 B细胞转录印记是否得以维持
在 T2/MZP-MZ-FO 发育阶段;以及 (3) 确定 T1 B 细胞内源性 IFNβ 是否促进某种类型
I IFN 网络可抑制 SLE 患者 T1 阶段调节性 B 细胞的前体细胞。
拟议工作的科学前提包括 T1 B 细胞转录谱之间的相似性
和成熟 B 细胞以及 I 型 IFN 相关与 Breg 相关转录谱的分离
我们已经获得了 IFNβ、IL-10、Foxp3 和 Id3 的报告小鼠品系,以进行谨慎的询问。
过渡性 T1 B 子集内或衍生自过渡性 T1 B 子集的发育阶段。
获得的信息将对该领域产生广泛的影响,并改善退伍军人事务部患者的护理
通过确定提高靶向生物疗法与非药物疗法疗效的策略来治疗 SLE
侵入性精准医学引导方法。
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Dynamic Duo-Inflammatory M1 macrophages and Th17 cells in Rheumatic Diseases.
风湿病中的动态双炎症 M1 巨噬细胞和 Th17 细胞。
- DOI:10.13188/2334-2846.1000002
- 发表时间:2013-11-01
- 期刊:
- 影响因子:0
- 作者:Li J;Hsu HC;Mountz JD
- 通讯作者:Mountz JD
Identification of follicular T helper cells in tissue sections.
组织切片中滤泡 T 辅助细胞的鉴定。
- DOI:
- 发表时间:2015
- 期刊:
- 影响因子:0
- 作者:Ding, Yanna;Mountz, John D;Hsu, Hui
- 通讯作者:Hsu, Hui
Editorial: STATus of STAT3 in Psoriatic Arthritis.
社论:STAT3 在银屑病关节炎中的现状。
- DOI:
- 发表时间:2018-06
- 期刊:
- 影响因子:0
- 作者:Mountz; John D
- 通讯作者:John D
Interrelation of T cell cytokines and autoantibodies in systemic lupus erythematosus: A cross-sectional study.
系统性红斑狼疮中 T 细胞细胞因子和自身抗体的相互关系:一项横断面研究。
- DOI:10.1016/j.clim.2023.109239
- 发表时间:2023-01-01
- 期刊:
- 影响因子:8.6
- 作者:Fatima Alduraibi;K. Sullivan;W. Chatham;H. Hsu;J. Mountz
- 通讯作者:J. Mountz
IL-23 Promotes a Coordinated B Cell Germinal Center Program for Class-Switch Recombination to IgG2b in BXD2 Mice.
IL-23 促进 BXD2 小鼠中协调的 B 细胞生发中心程序,实现类别转换重组为 IgG2b。
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Hong, Huixian;Gao, Min;Wu, Qi;Yang, PingAr;Liu, Shanrun;Li, Hao;Burrows, Peter D;Cua, Daniel;Chen, Jake Y;Hsu, Hui;Mountz, John D
- 通讯作者:Mountz, John D
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John D Mountz其他文献
John D Mountz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John D Mountz', 18)}}的其他基金
B-cell innate and adaptive protective immunity to SARS-CoV-2
B 细胞对 SARS-CoV-2 的先天性和适应性保护性免疫
- 批准号:
10778521 - 财政年份:2021
- 资助金额:
-- - 项目类别:
B-cell innate and adaptive protective immunity to SARS-CoV-2
B 细胞对 SARS-CoV-2 的先天性和适应性保护性免疫
- 批准号:
10154041 - 财政年份:2021
- 资助金额:
-- - 项目类别:
B-cell innate and adaptive protective immunity to SARS-CoV-2
B 细胞对 SARS-CoV-2 的先天性和适应性保护性免疫
- 批准号:
10341174 - 财政年份:2021
- 资助金额:
-- - 项目类别:
B cell intrinsic interferon-beta regulates autoreactive B cell development
B 细胞内在干扰素-β 调节自身反应性 B 细胞发育
- 批准号:
10326335 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Interferon Beta Initiated Development of Immunogenic T1 B cells in Lupus
干扰素 Beta 启动狼疮中免疫原性 T1 B 细胞的发育
- 批准号:
10046270 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Training Program in Rheumatic and Musculoskeletal Diseases Research
风湿病和肌肉骨骼疾病研究培训计划
- 批准号:
10628089 - 财政年份:2016
- 资助金额:
-- - 项目类别:
ROS Modulation of Innate and Adaptive Immunity in RA
ROS 对 RA 先天性和适应性免疫的调节
- 批准号:
8309519 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Role of ST6Gal I-Mediated Receptor Sialylation in Autoimmune Disease
ST6Gal I 介导的受体唾液酸化在自身免疫性疾病中的作用
- 批准号:
8309520 - 财政年份:2011
- 资助金额:
-- - 项目类别:
相似国自然基金
基于溶酶体依赖性凋亡及抗原呈递功能的GL-V9抗AML作用的研究
- 批准号:82173847
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
超抗原SEB在慢性鼻-鼻窦炎的发病过程中对鼻黏膜上皮屏障功能的影响与机制研究
- 批准号:81900915
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
Spag6基因缺陷致小鼠前庭功能异常的机制研究
- 批准号:81900940
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
Tn抗原通过DR4/DR5调控结直肠癌细胞对TRAIL敏感性的机制研究
- 批准号:81902800
- 批准年份:2019
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
转录因子BORIS转位线粒体调控结直肠癌发生发展的机制研究
- 批准号:31871393
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:面上项目
相似海外基金
Source and homeostatic functions of anti-adduct IgM in humans
人类抗加合物 IgM 的来源和稳态功能
- 批准号:
10680950 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Flt3l gene-modified cDC1 in situ vaccination in NSCLC: mechanisms and therapeutic application
Flt3l 基因修饰的 cDC1 原位疫苗接种在 NSCLC 中的作用:机制和治疗应用
- 批准号:
10585591 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Radiation Mitigators Targeting Regulated Necrosis Pathways of Parthanatos Pyroptosis
针对帕塔纳托细胞焦亡的调节性坏死途径的辐射缓解剂
- 批准号:
10838232 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Elucidating and harnessing the molecular mechanisms of protective clearance in endogenous and engineered phagocytes
阐明和利用内源性和工程化吞噬细胞保护性清除的分子机制
- 批准号:
10729935 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Diagnostic utility of antibodies to post-translationally modified nucleosomes in lupus nephritis
翻译后修饰核小体抗体在狼疮性肾炎中的诊断效用
- 批准号:
10683684 - 财政年份:2023
- 资助金额:
-- - 项目类别: